Sanofi S.A. Company Analysis & Research
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The company discovers, develops, manufactures, and markets an array of medicines and vaccines, with its portfolio including medicines for cancer, rare diseases, and multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products.
In 2025, sales increased by 9.9% at constant exchange rates, while business EPS improved significantly faster by 15.0%. The company leverages AI-driven supply chain management that enabled it to avoid $300 million in revenue risk, and combining machine learning with lab research has helped discover 10 completely new drug targets in just one year.
Company Overview
Founded: 1973. Headquarters: Paris, France. Revenue: EUR 43.6B (2025). Ticker: SNY (NASDAQ).
Industry
Biopharmaceuticals - Pharmaceuticals & Vaccines
Cyborg Score: 8/10 — Strong
Sanofi is a well-positioned global pharma leader with strong 2025 momentum, innovative pipeline delivery, and AI-driven transformation driving margin expansion.
Sanofi reported 9.9% sales growth for 2025, reaching EUR 43.6 billion, and delivered 13.3% sales growth in Q4. The company expects sales to grow by a high single-digit percentage in 2026 with business EPS growing slightly faster than sales. Strong pipeline execution and AI integration position the company well, though patent cliffs and pricing pressures present ongoing challenges.
Key Strategic Insights for Sanofi S.A.
- Dupixent achieved EUR 15.7 billion in sales with over 30% patient growth, while three new medicines and vaccines (Qfitlia, Wayrilz, Nuvaxovid) were launched in 2025 and ALTUVIIIO and Beyfortus achieved blockbuster status.
- The company delivered 12 Phase III and 15 Phase II readouts, 20 regulatory approvals, and multiple late-stage programs advancing in 2025.
- AI agents are actively shaping decision-making in drug development, assessing whether drugs should advance to the next trial phase and comparing asset prospects against others in development.
- Sanofi reached agreement with the US government to lower medicine costs while strengthening innovation.
Recent Developments
- (January 2026) Strategic investment of up to $25 million in Adagene for masked antibody therapy collaboration
- (December 2025) Acquired Dynavax to add hepatitis B vaccine and shingles candidate to portfolio
- (December 2025) Wayrilz approved in EU as first BTK inhibitor for immune thrombocytopenia
- (January 2026) Tzield accepted for priority review in US for young children with type 1 diabetes
Competitors & Competitive Landscape
- Sanofi — Leading biologic for atopic dermatitis and other inflammatory conditions
- Merck — Leading oncology immunotherapy
- AbbVie — JAK inhibitor for inflammatory conditions
- Amgen — Small molecule immunology therapy
Top competitors include Merck, AbbVie, and Amgen. Sanofi competes in highly competitive specialty pharma and vaccine markets with other diversified players like Johnson & Johnson, Roche, and Novartis, differentiating through its large portfolio breadth, emerging vaccine franchise, and rare disease expertise.
More Company Research
Enviva Inc. Zoomd Technologies Ltd. Tabuk Cement Company Ashtead Technology Holdings PLC Gokaldas Exports Limited MPC Container Ships ASA Nittetsu Mining Co., Ltd. Resolute Mining Limited Home Product Center Public Company Limited Amneal Pharmaceuticals, Inc. PGE Polska Grupa Energetyczna S.A. HealthEquity, Inc. Fidelity National Financial, Inc. Dollar General Corporation Exxon Mobil CorporationFull Company Research Reports
Looking for a more in-depth analysis of Sanofi S.A.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.